• Alnylam Pharmaceuticals reported initial Phase 1b results showing sustained mutant huntingtin lowering with brezosiran in Huntington’s disease, with encouraging safety and tolerability.
• The findings support potential twice-yearly dosing; results were presented at the European Huntington’s Disease Network Clinical Research Congress 2026.
• A placebo-controlled pivotal study is planned for 2027, pending regulatory alignment, to assess whether brezosiran can slow disease progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230345BIZWIRE_USPR_____20261023_BW812467) on October 23, 2026, and is solely responsible for the information contained therein.